Venrock Adviser, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001615982

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 33 positions · Total reported value $3.30B · Top-10 concentration 80.4% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 35.1% · 4 new · 5 cut · 4 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +24.9% · vs SPY +10.0% · Prev Value $2.68B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Venrock Adviser, LLC disclosed 33 equity positions with a combined reported value of $3.30B. The filing implies a focused portfolio: its ten largest positions account for 80.4% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were APGE ($1.13B), ORKA ($394.81M), ERAS ($327.78M). By sector, the heaviest allocations are Health Care 65.7%, Financials 0.1%. Versus the prior quarter, allocation shifted toward Other (+2.6pp) and away from Health Care (-2.7pp).

Versus the prior quarter, Venrock Adviser, LLC opened 4 new positions, trimmed 5 and fully exited 4, a turnover rate of 35.1% of positions. The portfolio's overlap with the prior quarter was 78% of names.

The largest new positions opened in Q2 2026 were ACHV ($17.96M), PBLS ($17.11M), RACC ($3.21M).

Of the 4 positions fully exited versus the prior quarter, the largest were KALV ($130.33M), ENGN ($32.49M), TENX ($26.79M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • ACHV ACHIEVE LIFE SCIENCES INC · $17.96M
  • PBLS PARABILIS MEDICINES INC · $17.11M
  • RACC RESEARCH ALLIANCE CORP III · $3.21M
  • INM InMed Pharmaceuticals Inc · $50.66K

Fully Exited (vs previous quarter)

  • KALV KALVISTA PHARMACEUTICALS INC · prev qtr: $130.33M
  • ENGN ENGENE THERAPEUTICS INC · prev qtr: $32.49M
  • TENX TENAX THERAPEUTICS INC · prev qtr: $26.79M
  • SEPN SEPTERNA INC · prev qtr: $12.16M

Insider Transactions (Form 4)

Latest Venrock Adviser, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Venrock Adviser, LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 33 US equity positions with a combined value of $3.30B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-79382 (status: Approved), registered 2014-04-09
  • Regulatory AUM (Form ADV): $4.50B as of 2026-04-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 7 private funds, of which 1 hedge funds

Portfolio Structure

  • 33 positions · $3.30B reported value (Q2 2026)
  • Top 10 holdings = 80.4% of reported value
  • Largest position: APGE (APOGEE THERAPEUTICS INC) at 34.2%
  • Average position size: $99.94M

Sector Tilt

  • Health Care 65.7%
  • Financials 0.1%
  • (classified holdings cover 66% of value)

Quarterly Activity

  • Q2 2026: 4 new, 5 added, 5 reduced, 4 exited
  • 19 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a cautiously optimistic stance on the healthcare sector, with a focus on biotechnology and life sciences. The quarter-over-quarter changes indicate a slight preference for growth and innovation in this sector. 2. Key Moves: - Added: Erasca Inc. (ERAS) with a significant increase of 9.2% in shares, indicating a strong belief in the company's potential. - Reduced: Cogent Biosciences Inc. (COGT) with a 17.9% decrease in shares, suggesting a shift away from this particular stock. - No Change: The holdings in Apogee Therapeutics Inc. (APGE), Orka Therapeutics Inc. (ORKA), Dianthus Therapeutics Inc. (DNTH), Ocular Therapeutix Inc. (OCUL), Damora Therapeutics Inc. (DMRA), Savara Inc. (SVRA), and Jade Biosciences Inc. (JABO) remained consistent, indicating a stable position in these companies. 3. Portfolio Structure: The portfolio appears to be actively managed, with a bias towards healthcare, particularly biotechnology. The addition of Erasca Inc. and Savara Inc. suggests a willingness to take on riskier, potentially high-growth investments. The overall risk appetite seems moderate, as the fund maintains a diversified approach within the healthcare sector. 4. Per-Holding One-Liner: - APGE: Apogee Therapeutics Inc. – Developing treatments for rare and orphan diseases. - ORKA: Orka Therapeutics Inc. – Focused on developing therapies for rare genetic diseases. - ERAS: Erasca Inc. – Engaged in the discovery and development of novel cancer therapies. - SYRE: Spire Therapeutics Inc. – Specializes in the development of therapies for central nervous system disorders. - DNTH: Dianthus Therapeutics Inc. – Working on treatments for cancer and other diseases. - OCUL: Ocular Therapeutix Inc. – Focuses on the development of therapies for eye diseases. - DMRA: Damora Therapeutics Inc. – Developing novel treatments for respiratory diseases. - SVRA: Savara Inc. – Specializes in the development of therapies for respiratory conditions. - JBIO: Jade Biosciences Inc. – Engaged in the development of novel treatments for cancer. - COGT: Cogent Biosciences Inc. – Developing therapies for cancer and autoimmune diseases. 5. One-Sentence Style Summary: Venrock Adviser, LLC maintained a diversified healthcare portfolio in Q2 2026, with a strategic addition of Erasca Inc. to its holdings, indicating a focus on innovative biotechnology and life sciences.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 65.7%
Financials 0.1%
Other 34.2%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 8.49M $1.13B 34.18%
34.18%
Hold
2 4.15M $394.81M 11.97%
11.97%
Hold
3 17.89M $327.78M 9.94%
9.94%
Add
4 2.99M $265.05M 8.04%
8.04%
Reduce
5 1.18M $115.03M 3.49%
3.49%
Hold
6 10.35M $101.61M 3.08%
3.08%
Hold
7 3.60M $93.73M 2.84%
2.84%
Hold
8 14.75M $90.84M 2.75%
2.75%
Add
9 3.22M $71.56M 2.17%
2.17%
Hold
10 1.64M $63.55M 1.93%
1.93%
Reduce
11 3.26M $59.85M 1.81%
1.81%
Reduce
12 3.04M $56.00M 1.70%
1.70%
Hold
13 2.17M $48.28M 1.46%
1.46%
Hold
14 1.60M $47.80M 1.45%
1.45%
Hold
15 6.84M $47.36M 1.44%
1.44%
Add
16 4.32M $46.78M 1.42%
1.42%
Hold
17 2.13M $38.40M 1.16%
1.16%
Hold
18 6.43M $37.97M 1.15%
1.15%
Hold
19 3.21M $36.95M 1.12%
1.12%
Hold
20 526.33K $26.71M 0.81%
0.81%
Reduce
21 3.85M $25.46M 0.77%
0.77%
Hold
22 1.38M $25.13M 0.76%
0.76%
Hold
23 8.70M $21.30M 0.65%
0.65%
Hold
24 2.04M $19.82M 0.60%
0.60%
Add
25 4.98M $18.68M 0.57%
0.57%
Reduce
26 2.75M $17.96M 0.55%
0.55%
New
27 625.00K $17.11M 0.52%
0.52%
New
28 632.93K $16.42M 0.50%
0.50%
Hold
29 1.01M $13.31M 0.40%
0.40%
Hold
30 500.00K $13.20M 0.40%
0.40%
Hold
31 1.93M $9.03M 0.27%
0.27%
Add
32 300.00K $3.21M 0.10%
0.10%
New
33 32.69K $50.66K 0.00%
0.00%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 80% R 80% F1 80% (modelled on 2026-Q1; 8/10 hit)

Historical Backtest (10 quarters)

Avg precision 80% · recall 80% · F1 80% · avg rank error 2.5 · Top-10 turnover 19%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 80% 80% 80% RYZB · APGE · PHVS · VRDN · FDMT · MRUS · CABA · KALV · SYRE · ELVN APGE · FDMT · OCUL · SYRE · MRUS · PHVS · KALV · ELVN · VRDN · DNTH
2024-Q2 90% 90% 90% APGE · FDMT · OCUL · PHVS · KALV · MRUS · SYRE · ELVN · DNTH · VRDN APGE · ELVN · FDMT · OCUL · DYN · MRUS · KALV · PHVS · SYRE · DNTH
2024-Q3 70% 70% 70% APGE · ELVN · FDMT · OCUL · KALV · DYN · MRUS · SYRE · PHVS · DNTH APGE · OCUL · ELVN · VRDN · APLT · SYRE · DYN · ORKA · KALV · PHVS
2024-Q4 90% 90% 90% APGE · OCUL · ELVN · VRDN · APLT · SYRE · DYN · ORKA · KALV · PHVS APGE · OCUL · ELVN · PRAX · VRDN · ORKA · SYRE · PHVS · KALV · DYN
2025-Q1 90% 90% 90% APGE · OCUL · ELVN · PRAX · VRDN · ORKA · SYRE · PHVS · KALV · DYN APGE · MTSR · OCUL · ELVN · KALV · VRDN · PHVS · SYRE · ORKA · PRAX
2025-Q2 90% 90% 90% APGE · MTSR · OCUL · ELVN · KALV · VRDN · PHVS · ORKA · SYRE · PRAX APGE · OCUL · MTSR · ELVN · KALV · ORIC · VRDN · ORKA · SYRE · PHVS
2025-Q3 80% 80% 80% APGE · OCUL · MTSR · ELVN · KALV · ORIC · VRDN · ORKA · SYRE · PHVS APGE · MTSR · OCUL · CDTX · VRDN · KALV · ORKA · ORIC · ELVN · COGT
2025-Q4 60% 60% 60% APGE · MTSR · OCUL · CDTX · ORIC · VRDN · KALV · ORKA · ELVN · COGT APGE · ORKA · VRDN · SYRE · KALV · OCUL · SVRA · COGT · ERAS · CTMX
2026-Q1 70% 70% 70% APGE · SYRE · ORKA · VRDN · KALV · SVRA · OCUL · MAZE · CTMX · ERAS APGE · ERAS · ORKA · SYRE · KALV · DNTH · DMRA · OCUL · COGT · VRDN
2026-Q2 ★ 80% 80% 80% APGE · ERAS · ORKA · SYRE · KALV · DNTH · DMRA · OCUL · VRDN · SVRA APGE · ORKA · ERAS · SYRE · DNTH · OCUL · DMRA · SVRA · JBIO · COGT

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Venrock Adviser, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Venrock Adviser, LLC reported 33 equity positions worth $3.30B in aggregate; its largest disclosed positions were APGE ($1.13B), ORKA ($394.81M), ERAS ($327.78M).

How large is Venrock Adviser, LLC's portfolio?

Venrock Adviser, LLC reported $3.30B of long equity holdings across 33 positions as of 2026-Q2. Top-10 holdings account for 80.4% of reported value.

What is Venrock Adviser, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/venrock-adviser/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →